Lutetium-177 (Lu-177) Chloride for Targeted Radiotherapy
Lutetium-177 (Lu-177) is a leading radionuclide for targeted molecular radiotherapy, widely used in the treatment of neuroendocrine tumors and prostate cancer (mCRPC).
As a theranostic isotope, Lu-177 enables precise tumor targeting and monitoring, with proven clinical benefits in progression-free survival and quality of life.
Comprehensive Lu-177 Solutions
Isotopia is the only global provider offering both no-carrier-added (n.c.a.) and carrier-added (c.a.) Lu-177, ensuring flexibility for diverse clinical and manufacturing needs.
Our Lu-177 is produced under strict cGMP standards and conforms to the European Pharmacopeia monograph, guaranteeing quality and compliance:
- EU Marketing authorisation for c.a.
- US DMF for n.c.a. and c.a.
- Canadian MF for n.c.a.
Comprehensive Lu-177 Solutions
Global, Reliable Supply
With production sites in Israel, USA, and Austria, Isotopia ensures uninterrupted, weekly Lu-177 deliveries worldwide. Our robust multi-site network and planned expansion into Asia provide:
• Consistent, on-time supply for any quantity required
• Full regulatory compliance and documentation
• Responsive technical and logistical support.
Why Partner with Isotopia?
• Dual n.c.a. and c.a. Lu-177 to match your application
• Tri-continental manufacturing for supply chain security
• Proven track record in supporting clinical and commercial radiopharmaceutical programs
• Dedicated customer service and expert guidance
Contact us today to discuss your Lu-177 requirements and experience reliable, high-quality supply for your radiopharmaceutical needs.
I want more details please
